Atossa Therapeutics, Inc.
ATOS
$0.823
-$0.011-1.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.26M | 3.75M | 2.97M | 3.55M | 3.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.41M | 7.15M | 6.39M | 7.11M | 6.98M |
| Operating Income | -7.41M | -7.15M | -6.39M | -7.11M | -6.98M |
| Income Before Tax | -6.72M | -6.35M | -7.23M | -6.05M | -5.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.72M | -6.35M | -7.23M | -6.05M | -5.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.72M | -6.35M | -7.23M | -6.05M | -5.88M |
| EBIT | -7.41M | -7.15M | -6.39M | -7.11M | -6.98M |
| EBITDA | -7.41M | -7.15M | -6.38M | -7.10M | -6.98M |
| EPS Basic | -0.05 | -0.05 | -0.06 | -0.05 | -0.05 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| EPS Diluted | -0.05 | -0.05 | -0.06 | -0.05 | -0.05 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 129.17M | 126.61M | 125.77M | 125.73M | 125.32M |
| Average Diluted Shares Outstanding | 129.17M | 126.61M | 125.77M | 125.73M | 125.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |